Evaluation of corticophobia in patients with atopic dermatitis and psoriasis using the TOPICOP© score
Authors:
- 30 December 2023
- journal article
- research article
- Published by Association of Slovenian Dermatovenerologists in Acta Dermatovenerologica Alpina Pannonica et Adriatica
- Vol. 32 (4) , 135-139
Abstract
Atopic dermatitis (AD) and psoriasis (PS) are skin diseases that have a significant impact on the quality of life. The correct application of corticosteroids in topical treatment is highly effective and safe for patients. Excessive and irrational fear of these drugs based on incorrect information is increasingly observed at dermatological clinics. To assess the extent of corticophobia, we conducted a single-center cross-sectional survey using the TOPICOP© questionnaire. The study included 57 patients (56% female) with AD and 58 patients (60% female) with PS. The combined TOPICOP© score averaged around 44, showing no significant difference between the two skin conditions. However, consistently higher scores were observed among female participants compared to males. The prevalence of corticophobia was comparable to that reported in other similar studies and was higher among female patients, which replicates previous findings. Patients with AD, who were younger on average than patients with PS, often relied on friends, acquaintances, family members, and the internet as their main information sources. Providing correct and reliable information to patients is crucial for ensuring treatment adherence.Keywords
This publication has 25 references indexed in Scilit:
- Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP scoreAllergy, 2017
- Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasisJournal of the European Academy of Dermatology and Venereology, 2017
- Systemic Side-Effects of Topical CorticosteroidsIndian Journal of Dermatology, 2014
- Atopic Dermatitis: Natural History, Diagnosis, and TreatmentISRN Allergy, 2014
- TOPICOP©: A New Scale Evaluating Topical Corticosteroid Phobia among Atopic Dermatitis Outpatients and Their ParentsPLOS ONE, 2013
- SCORAD reflects the duration of atopic dermatitis lesionsIndian Journal of Dermatology, 2013
- European S3‐Guidelines on the systemic treatment of psoriasis vulgarisJournal of the European Academy of Dermatology and Venereology, 2009
- PsoriasisNew England Journal of Medicine, 2005
- Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their qualityBritish Journal of Dermatology, 1999
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994